The information in Table 3 outlines the effectiveness of 68Ga-PSMA PET/CT and mpMRI in detecting ECE in prostate cancer, with a collective sensitivity of 0.43 (95% CI:0.24-0.64) and 0.66 (95% CI:0.41-0.87) respectively. This evidence concerns the gene FOLH1 and prostate carcinoma.